Skip to content
Screener

Amylyx Pharmaceuticals, Inc. AMLX Q2 2026 earnings

Reported August 6, 2026 · Before market open

EPS-$0.39Miss by $0.03
EPS estimate-$0.36

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$59.4K
EPS estimate-$0.38

Financials

Q2 2026

Income statement

See full
Operating income-$45.7M-6.6%
Net income-$43.4M-4.8%
EPS (diluted)-$0.39+15.2%

Balance sheet

See full
Cash & equivalents$49.3M-15.1%
Total debt$5.3M-11.9%
Total equity$239.2M+42.5%
Total assets$264.6M+36.0%

Cash flow

See full
Operating cash flow-$31.4M-24.5%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$3.64B+167%
Enterprise value$3.59B+174%

Returns & leverage

See full
Return on equity-74.7%-9.5pp
Debt / equity0×0.0×
Current ratio12.1×+3.4×

FAQ

When did Amylyx Pharmaceuticals, Inc. report Q2 2026 earnings?
Amylyx Pharmaceuticals, Inc. (AMLX) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Amylyx Pharmaceuticals, Inc.'s Q2 2026 revenue and EPS?
Amylyx Pharmaceuticals, Inc. reported eps of $-0.39 for Q2 2026.
Did Amylyx Pharmaceuticals, Inc. beat estimates in Q2 2026?
EPS missed the consensus estimate of $-0.36 by $0.03.
How did Amylyx Pharmaceuticals, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 15.2% from $-0.46.
Where can I find Amylyx Pharmaceuticals, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-336670) and the 10-Q periodic report (0001193125-26-336682) directly on SEC EDGAR. The filing index links above go to sec.gov.